Microbial Signature in Adipose Tissue of Crohn’s Disease Patients

Crohn’s disease (CD) is characterized by compromised immune tolerance to the intestinal commensal microbiota, intestinal barrier inflammation, and hyperplasia of creeping fat (CF) and mesenteric adipose tissue (AT), which seems to be directly related to disease activity. Gut microbiota dysbiosis might be a determining factor in CD etiology, manifesting as a low microbial diversity and a high abundance of potentially pathogenic bacteria. We tested the hypothesis that CF is a reservoir of bacteria through 16S-rRNA sequencing of several AT depots of patients with active and inactive disease and controls. We found a microbiome signature within CF and mesenteric AT from patients, but not in subcutaneous fat. We failed to detect bacterial DNA in any fat depot of controls. Proteobacteria was the most abundant phylum in both CF and mesenteric AT, and positively correlated with fecal calprotectin/C-reactive protein. Notably, the clinical status of patients seemed to be related to the microbiome signature, as those with the inactive disease showed a reduction in the abundance of pathogenic bacteria. Predictive functional profiling revealed many metabolic pathways including lipopolysaccharide biosynthesis and sulfur metabolism overrepresented in active CD relative to that in inactive CD. Our findings demonstrate that microbiota dysbiosis associated with CD pathophysiology is reflected in AT and might contribute to disease severity.

[1]  Patrice D Cani,et al.  Microbial signatures in metabolic tissues: a novel paradigm for obesity and diabetes? , 2020, Nature metabolism.

[2]  M. Surette,et al.  Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity , 2020, Nature Metabolism.

[3]  J. Vadivelu,et al.  Prevalence and association of pks+ Escherichia coli with colorectal cancer in patients at the University Malaya Medical Centre, Malaysia , 2020, PloS one.

[4]  D. Charnock-Jones,et al.  Human placenta has no microbiome but can harbour potential pathogens , 2019, Nature.

[5]  Zhenhua Zhu,et al.  Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease , 2019, World journal of gastroenterology.

[6]  M. Silverberg,et al.  257 – Higher Abundance of Bile Acid-Metabolizing Microbiota is Associated with Type of Disease, Biopsy Location and Mucosal Inflammation in Inflammatory Bowel Disease Patients , 2019, Gastroenterology.

[7]  Dara Walsh,et al.  AB060. 207. Digital reconstruction of human mesentery development , 2019, Mesentery and Peritoneum.

[8]  H. Yao,et al.  Fusobacterium and Colorectal Cancer , 2018, Front. Oncol..

[9]  F. Tinahones,et al.  Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study , 2018, Diabetes Care.

[10]  F. Shanahan,et al.  Inclusion of the Mesentery in Ileocolic Resection for Crohn’s Disease is Associated With Reduced Surgical Recurrence , 2018, Journal of Crohn's & colitis.

[11]  I. Moreno-Indias,et al.  Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes Mellitus , 2017, Front. Microbiol..

[12]  N. Borruel,et al.  Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation , 2017, Stem cell reports.

[13]  N. Hu,et al.  Molecular Characterization of the Human Stomach Microbiota in Gastric Cancer Patients , 2017, Front. Cell. Infect. Microbiol..

[14]  F. Crea,et al.  Epicardial adipose tissue microbial colonization and inflammasome activation in acute coronary syndrome. , 2017, International journal of cardiology.

[15]  Weiming Zhu,et al.  The role of the mesentery in Crohn's disease. , 2017, The lancet. Gastroenterology & hepatology.

[16]  Harry Sokol,et al.  A microbial signature for Crohn's disease , 2017, Gut.

[17]  D. O'Leary,et al.  The mesentery: structure, function, and role in disease. , 2016, The lancet. Gastroenterology & hepatology.

[18]  J. Vendrell,et al.  Obesity and Type 2 Diabetes Alters the Immune Properties of Human Adipose Derived Stem Cells , 2016, Stem cells.

[19]  Krishna R. Kalari,et al.  The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease , 2016, Scientific Reports.

[20]  C. Consolandi,et al.  Adipose tissue microbiota in humans: an open issue , 2016, International Journal of Obesity.

[21]  Sandra Santos Doença de Crohn: fator de risco para o carcinoma colorretal , 2016 .

[22]  Chittaranjan S. Yajnik,et al.  Molecular Characterization and Meta-Analysis of Gut Microbial Communities Illustrate Enrichment of Prevotella and Megasphaera in Indian Subjects , 2016, Front. Microbiol..

[23]  M. Leclerc,et al.  Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? , 2016, Front. Microbiol..

[24]  S. Salminen,et al.  Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid , 2016, Scientific Reports.

[25]  R. Simó,et al.  Obesity Determines the Immunophenotypic Profile and Functional Characteristics of Human Mesenchymal Stem Cells From Adipose Tissue , 2016, Stem cells translational medicine.

[26]  F. Servant,et al.  The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline , 2015, PloS one.

[27]  Luzia Valentini,et al.  Visceral Adipose Tissue in Patients with Crohn's Disease Correlates with Disease Activity, Inflammatory Markers, and Outcome , 2015, Inflammatory bowel diseases.

[28]  K. Aagaard,et al.  The preterm placental microbiome varies in association with excess maternal gestational weight gain. , 2015, American journal of obstetrics and gynecology.

[29]  Bernard M. Corfe,et al.  Dysbiosis of the gut microbiota in disease , 2015, Microbial ecology in health and disease.

[30]  F. Magro,et al.  Metabolic Inflammation in Inflammatory Bowel Disease: Crosstalk Between Adipose Tissue and Bowel , 2015, Inflammatory bowel diseases.

[31]  E. Allen-Vercoe,et al.  Fusobacterium and Enterobacteriaceae: important players for CRC? , 2014, Immunology letters.

[32]  J. Petrosino,et al.  The Placenta Harbors a Unique Microbiome , 2014, Science Translational Medicine.

[33]  C. Invitti,et al.  Differences in Visceral Fat and Fat Bacterial Colonization between Ulcerative Colitis and Crohn’s Disease. An In Vivo and In Vitro Study , 2013, PloS one.

[34]  R. Burcelin,et al.  Metagenome and metabolism: the tissue microbiota hypothesis , 2013, Diabetes, obesity & metabolism.

[35]  C. Manichanh,et al.  Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.

[36]  R. Juza,et al.  Volumetric Fat Ratio and Not Body Mass Index Is Predictive of Ileocolectomy Outcomes in Crohn's Disease Patients , 2013, Digestive Surgery.

[37]  G. Rogler,et al.  Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease , 2013, Gut.

[38]  Karsten Zengler,et al.  The microbiome extends to subepidermal compartments of normal skin , 2012, Nature Communications.

[39]  H. Gaskins,et al.  Microbial pathways in colonic sulfur metabolism and links with health and disease , 2012, Front. Physio..

[40]  Francisco Guarner,et al.  The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.

[41]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[42]  S. Mazmanian,et al.  Intestinal Microbes in Inflammatory Bowel Diseases , 2012 .

[43]  S. Ng,et al.  Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota* , 2012, Inflammatory bowel diseases.

[44]  B. Birren,et al.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.

[45]  Richard A. Moore,et al.  Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.

[46]  B. Siegmund Mesenteric fat in Crohn's disease: the hot spot of inflammation? , 2011, Gut.

[47]  Tarah Lynch,et al.  Invasive potential of gut mucosa‐derived fusobacterium nucleatum positively correlates with IBD status of the host , 2011, Inflammatory bowel diseases.

[48]  B. Chassaing,et al.  The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. , 2011, Gastroenterology.

[49]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[50]  H. Tajiri,et al.  Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. , 2009, Journal of medical microbiology.

[51]  N. Borruel,et al.  Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa , 2009, Inflammatory bowel diseases.

[52]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[53]  H. Freeman Colorectal cancer risk in Crohn's disease. , 2008, World journal of gastroenterology.

[54]  B. Finlay,et al.  Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. , 2007, Cell host & microbe.

[55]  U. Gophna,et al.  Differences between Tissue-Associated Intestinal Microfloras of Patients with Crohn's Disease and Ulcerative Colitis , 2006, Journal of Clinical Microbiology.

[56]  Philippe Marteau,et al.  Specificities of the fecal microbiota in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[57]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[58]  Laurent Beaugerie,et al.  High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. , 2004, Gastroenterology.

[59]  J. Hampe,et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.

[60]  T. Ohkusa,et al.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis , 2003, Gut.

[61]  T. Ohkusa,et al.  Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species‐specific antibody , 2002, Journal of gastroenterology and hepatology.

[62]  D. Jewell,et al.  Split ileostomy and ileocolostomy for Crohn's disease of the colon and ulcerative colitis: a 20 year survey. , 1983, Gut.

[63]  D. Jagelman,et al.  Loop lleostomy in the Management of Crohn's Colitis in the Debilitated Patient , 1980, Annals of surgery.

[64]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[65]  D. McIlrath Diverting ileostomy or colostomy in the management of Crohn's disease of the colon. , 1971, Archives of surgery.

[66]  L. Barbosa,et al.  Crohn's disease: risk factor for colorectal cancer , 2017 .

[67]  M. Toruner,et al.  Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). , 2014, Journal of Crohn's & colitis.

[68]  J. Colombel,et al.  [Bacterial translocation in Crohn disease]. , 1992, Gastroenterologie clinique et biologique.